<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795596</url>
  </required_header>
  <id_info>
    <org_study_id>388</org_study_id>
    <nct_id>NCT04795596</nct_id>
  </id_info>
  <brief_title>Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers</brief_title>
  <official_title>Clinical Outcomes of Secondary Cytoreductive Surgery in Platinum-resistant Ovarian Cancers With Isolated Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This novel study was specifically designed for platinum resistant recurrent ovarian cancers&#xD;
      and aimed to compare cases who received secondary cytoreductive surgery for isolated&#xD;
      recurrence and chemotherapy versus chemotherapy alone. This comparison will conduct the&#xD;
      intraoperative events, postoperative morbidity and mortality, pathological outcomes and&#xD;
      long-term oncological outcomes as regarding progression free survival and overall survival&#xD;
      rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline postoperative imaging with the use of abdominopelvic CT or MRI was to be completed&#xD;
      during a 28-day window in which chemotherapy was initiated. Disease is also assessed after&#xD;
      cycles 3 and 6 of trial treatment (and after cycle 8, if administered), every 3 months for 2&#xD;
      years, and then every 6 months thereafter. Physical examinations will be performed, and serum&#xD;
      CA-125 levels measured at the beginning of each cycle of chemotherapy. Treatment-free&#xD;
      interval (6 to 12 months or &gt;12 months after the last chemotherapy infusion) will be&#xD;
      reported.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>patients with platinum resistant cancer ovary will be randomized to one of two arms; either chemotherapy alone or surgical resection followed by chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>6 months from enrollment</time_frame>
    <description>the time interval between the first relapse and the second relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>18 months from enrollment</time_frame>
    <description>the time interval between the date of diagnosis till the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>6 months from enrollment</time_frame>
    <description>described according to the CTCAE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>surgery + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>surgical resection for recurrent platinum resistant ovarian cancer followed by second line chemotherapy as per the investigator's choice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>second line chemotherapy according to investigator's choice</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>secondary cytoreductive surgery</intervention_name>
    <description>resection of isolated recurrent ovarian carcinoma in platinum resistant disease</description>
    <arm_group_label>surgery + chemotherapy</arm_group_label>
    <other_name>re-resection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>second line chemotherapy according to investigator's choice</description>
    <arm_group_label>chemotherapy alone</arm_group_label>
    <arm_group_label>surgery + chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  platinum-resistant, recurrent epithelial ovarian cancer&#xD;
&#xD;
          -  amenable to complete gross resection, isolated recurrence&#xD;
&#xD;
          -  adequate renal, hepatic, and bone marrow function,&#xD;
&#xD;
          -  performance-status ECOG score of 0 to 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not medically fit for surgery&#xD;
&#xD;
          -  diffuse carcinomatosis, ascites, or extra-abdominal disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Sohaib, PhD/MD</last_name>
    <phone>+201060406063</phone>
    <email>dr.ahmed.sohaib@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Menoufia University, Faculty of medicine</name>
      <address>
        <city>ShibÄ«n Al Kawm</city>
        <state>Menoufia</state>
        <zip>32511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Sohaib, PhD/MD</last_name>
      <phone>01060406063</phone>
      <email>dr.ahmed.sohaib@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Reham A Abdel Aziz, PhD/MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amira H Hegazy, PhD/MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed H Elmeligy, PhD/MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Alhanafy, PhD/MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626.</citation>
    <PMID>31722153</PMID>
  </reference>
  <reference>
    <citation>Du Bois A, Vergote I, Ferron G et al. A randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 2017; 35(Suppl): abstr #5501</citation>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>Ahmed Sohaib</investigator_full_name>
    <investigator_title>Principal investigator, Lecturer of Clinical oncology</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>platinum resistant</keyword>
  <keyword>cytoreductive surgery</keyword>
  <keyword>recurrent ovarian cancer</keyword>
  <keyword>complete resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

